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Reports of unexplained discrepancies in the efﬁcacy of vaccines,
s estimated from randomised controlled trials in different parts of
he world, are commonplace in the literature [1–4]. Moreover, there
s a consistent trend for lower vaccine efﬁcacy when measured in
ettings where the disease of interest has a higher incidence, lead-
ng to questions about the appropriateness of pooled estimates.
ere, we examine the mathematical basis for such trends and pro-
ose a measure of efﬁcacy that is valid across settings. The approach
elies on ﬁtting mechanistic models, which specify pathogen expo-
ures and host responses, to global vaccine trial data stratiﬁed by
ocal disease incidence. Such models enable the estimation of vac-
ine protection per exposure to the pathogen. A strategy to estimate
er-exposure vaccine efﬁcacy will enable more accurate estimates
f vaccine efﬁcacy across a range of disease incidence [5].
. Minimal model for a clinical trial
Any analysis of a vaccine trial must compare the incidence of
isease in two groups of the population that are differentiated by
hether or not they have received the vaccine, here named the
accine group and the control group. Following Smith et al. [6]
nd Halloran et al. [7] for leaky vaccines, we denote by rc =  the
er capita rate of infection of unvaccinated individuals (force of
nfection) and by rv =  the reduced rate of infection in vacci-
ated subjects. The efﬁcacy of the vaccine is then represented by
 − rv/rc = 1 − . As noted by Smith et al. [6], this measure based
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264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article uon rate ratios is independent of time while a measure based on
risk ratios declines over time from the beginning of the trial due
to depletion of individuals at risk. Here, however, we are more
interested in stressing independence on the intensity of transmis-
sion that governs the incidence of disease, and focus on rate ratios
while Margheri et al. [9] elaborates on both rate and risk measures.
Despite these theoretical notions of independence, we encounter
a consistent trend of decreasing vaccine efﬁcacy with increasing
force of infection when estimated by conventional randomized
controlled trials.
2. Relaxing the model and adjusting the data
We extracted data on vaccine protection for tuberculosis (bacille
Calmette-Guérin, BCG [1]), rotavirus (pentavalent rotavirus vac-
cine, RotaTeq [2–4]), and malaria (RTS,S [10]), from systematic
reviews and recent multicenter clinical trials. These are plotted
in Fig. 1 to illustrate our argument (see appendix for tables). The
dashed lines represent 1 − , which we set at the level of the highest
protection estimate from any of the studies. As changing  basically
moves the lines up and down, it is evident that this cannot satisfac-
torily ﬁt the trends for reduced vaccine protection with increased
incidence seen from real life data. Based on the fact that individ-
ual risks of infection and disease are not homogeneous even in local
settings, a model can be developed that accounts for heterogeneous
distributions of individual risks [9,11], resulting in instanta-
neous rates written as rc(t) =
∫
xe−xtq(x)dx/
∫
e−xtq(x)dx and∫ ∫rv(t) = x  e−xtq(x)dx/ e−xtq(x)dx, where q(x) is the proba-
bility density function of individual risk. Heterogeneity induces a
cohort selection effect [12,13] whereby individuals at higher risk
are infected ﬁrst and leave behind less susceptible subjects. This
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Vaccine efﬁcacy on disease incidence gradients. (a) Tuberculosis [1]. (b)
Rotavirus [2–4]. (c) Malaria [10]. Solid curves are generated with the formula
1  − rv/rc, where rc and rv represent the incidence of infection in the control and
vaccine groups, over 1 year, and the labels indicate the variance of the risk distribu-
tion, q(x), in the absence of vaccination. Dash-dotted lines are the same measures
calculated over longer follow-up (2 years in the case of rotavirus, 4 years in the case
of  malaria). Data points come from settings where a trial has been conducted to
estimate vaccine efﬁcacy (Tables S1, S2, and S3), and dotted lines represent average
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mstimates by continent (America (magenta), Asia (blue), Africa (red)) taken from the
riginally published trial analyses.
esults in disease rates that decrease over time [14], an output
hat can be tested against time-to-event data. This effect is more
ronounced in the control group as individuals within it experi-
nce higher rates of infection overall. Consequently, the ratio of
isease rates in vaccinated over control groups increases, and vac-
ine efﬁcacy, as measured by simple rate ratios, decreases as the
rial progresses. Finally, the magnitude of this effect increases with
he intensity of transmission.
To illustrate the effect just described, we use a gamma  distri-
ution to represent heterogeneity in individual disease risk and
enerate the set of curves added to the plots in Fig. 1. Solid curves,
orresponding to 1-year follow-up, are labeled by the variance of
he respective gamma  distribution, which can be adjusted for best
tting the data (for the malaria trial we used a modiﬁed model
o account for repeated infections [9]). In the case of rotavirus and
alaria vaccines, we refer to recent trials, which conform with stan-
ardized multicenter designs, a highly desirable attribute for global
nalyses such as this. The original publications report follow-up
eriods of 2 years for rotavirus [2–4] and 4 years for malaria [10],
nd these prolonged durations are represented by the dash-dotted
urves. In any case, the trend of falling vaccine efﬁcacy with rising
isease incidence can be explained by a simple selection mech-
nism, which is not accounted for in standard trial analyses. The
easured variations in vaccine effects can be reproduced when a 34 (2016) 3007–3009
plausible model is ﬁtted to global data, stratiﬁed by country or some
other unit that enables the speciﬁcation of disease occurrence ratios
by incidence. The approach involves ﬁtting a curve to estimate two
parameters: the risk ratio of vaccine over control groups, ; and
the variance of the risk distribution in control groups, q(x). Vac-
cine efﬁcacy is then deﬁned as 1 − , representing, effectively, a
measure of efﬁcacy per unit of exposure, which has a clear inter-
pretation and can be used to parameterize predictive models of
vaccine protection in different incidence settings [15].
The procedure can be reﬁned as much as detailed attributes of
trial participants and pathogen types are collected and modeled,
although this requires access to original individual data, rather
than the aggregate measures that are usually published. The ﬁeld
would gain substantially if individual patient data were deposited
in repositories such as ImmPort or other public portals.
3. Observations from vaccine trials
Fig. 1 shows information retrieved from published vaccine trials.
Each data point comes from a country where a trial has been con-
ducted to estimate the efﬁcacy of a speciﬁc vaccine (colour coded
by continent). Dotted lines represent average estimates reported
in the original publications: BCG against pulmonary tuberculosis
[1]; RotaTeq against rotavirus gastroenteritis [2–4]; RTS,S against
malaria [10]. Three points are worth highlighting. The ﬁrst concerns
the reporting of overall estimates taken as averages. When varia-
tion in vaccine effects is large, pooled estimates have little meaning
as seen by comparing the dotted lines with the data points. The sec-
ond is that a suitable mathematical model can generate a family of
curves that describe the observed trends, and the parameters that
identify the best ﬁtting curve can be estimated by available sta-
tistical inference procedures [16–18]. The third is that the efﬁcacy
parameter obtained by this procedure approximates the vaccine
effect per unit of exposure [5].
4. Improving estimations from trials
There is overwhelming evidence that vaccine efﬁcacy, as com-
monly estimated in randomized controlled trials, decreases with
increasing disease incidence, but these observations can be recon-
ciled by making the analysis less rigid. We show that a plausible
model can reproduce the incidence-dependent observations when
adequately parameterized and give a vaccine efﬁcacy measure-
ment that is valid for all incidences. This universal efﬁcacy quantity
can be derived, by ﬁtting the model to vaccine trial data over a
gradient of incidences. Adjusting models to global data requires
ﬂexible distributions of individual disease risk to be implemented,
which can also be estimated in this process [19,20]. For illustration,
we have chosen three vaccines that have undergone randomized
controlled trials throughout the globe (BCG against pulmonary
tuberculosis [1], RotaTeq against rotavirus gastroenteritis [2–4] and
RTS,S against malaria [10]), but the procedure is applicable more
generally to vaccines and other interventions against not only infec-
tious diseases, but also non-communicable disorders provided that
information is available on exposure intensity to a speciﬁc risk
factor.
We hope to have laid the basis for further research on this impor-
tant topic where methodological development can be as elaborate
as the detail in available data allows. Per-exposure efﬁcacy can be
estimated by ﬁtting models to data from multicenter clinical tri-
als, ideally with study sites selected as to cover the largest possible
range of transmission intensities.
While here we  focus on the mathematical basis for the reported
trends, large studies are in progress to unravel biological determi-
nants of immune response to vaccines in a setting-speciﬁc manner.
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he two viewpoints are not exclusive but complementary, with
he possibility of each only partially explaining the observations.
urther studies are needed to identify how much of the trend
an be explained by the mathematical argument offered here.
ose−response experimental challenge systems are ideally suited
o this objective [8], and the recent attention devoted to the estab-
ishment of safe protocols applicable to human volunteers offers a
nique and exciting opportunity [21].
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